© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
ACADIA Pharmaceuticals Inc. (ACAD) stock surged +1.64%, trading at $26.72 on NASDAQ, up from the previous close of $26.29. The stock opened at $26.12, fluctuating between $26.05 and $26.95 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jan 20, 2026 | 25.72 | 26.32 | 25.25 | 26.29 | 1.25M |
| Jan 16, 2026 | 26.70 | 26.70 | 25.81 | 25.99 | 1.34M |
| Jan 15, 2026 | 26.99 | 27.06 | 26.42 | 26.53 | 998.18K |
| Jan 14, 2026 | 26.52 | 26.87 | 26.35 | 26.86 | 951.33K |
| Jan 13, 2026 | 26.96 | 26.98 | 26.01 | 26.46 | 1.14M |
| Jan 12, 2026 | 26.50 | 26.74 | 25.90 | 26.59 | 1.05M |
| Jan 09, 2026 | 26.94 | 27.20 | 26.49 | 26.78 | 756.23K |
| Jan 08, 2026 | 27.31 | 27.50 | 26.55 | 26.91 | 1.3M |
| Jan 07, 2026 | 27.12 | 27.74 | 27.05 | 27.42 | 1.61M |
| Jan 06, 2026 | 26.50 | 26.99 | 26.36 | 26.94 | 1.37M |
| Jan 05, 2026 | 26.17 | 26.60 | 25.56 | 26.15 | 1.37M |
| Jan 02, 2026 | 26.75 | 26.90 | 26.08 | 26.29 | 1.67M |
| Dec 31, 2025 | 26.70 | 26.87 | 26.64 | 26.71 | 753.14K |
| Dec 30, 2025 | 27.12 | 27.30 | 26.66 | 26.70 | 1.03M |
| Dec 29, 2025 | 27.53 | 27.62 | 27.07 | 27.26 | 981.98K |
| Dec 26, 2025 | 27.95 | 27.95 | 27.40 | 27.62 | 620.62K |
| Dec 24, 2025 | 27.95 | 27.96 | 27.65 | 27.87 | 500.09K |
| Dec 23, 2025 | 28.03 | 28.35 | 27.58 | 27.83 | 1.03M |
| Dec 22, 2025 | 27.16 | 28.26 | 26.92 | 28.06 | 1.59M |
| Dec 19, 2025 | 26.81 | 27.51 | 26.56 | 27.16 | 3.35M |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Employees | 653 |
| Beta | 0.68 |
| Sales or Revenue | $726.44M |
| 5Y Sales Change% | 1.508% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |